Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia
Interventions
DRUG

Bendamustine

Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.

DRUG

Clofarabine

Route of administration: IV days 1-5.

DRUG

Etoposide

Route of administration: IV days 1-5.

DRUG

Etoposide phosphate

Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.

DRUG

Dexamethasone

Route of administration: three times daily orally (by mouth), days 1-5.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

Teva Pharmaceuticals USA

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER

NCT01900509 - Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies | Biotech Hunter | Biotech Hunter